<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6456">
  <stage>Registered</stage>
  <submitdate>1/05/2017</submitdate>
  <approvaldate>1/05/2017</approvaldate>
  <nctid>NCT03138499</nctid>
  <trial_identification>
    <studytitle>A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,</studytitle>
    <scientifictitle>Randomized, Open-label, Phase 3 Trial of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Participants With Relapsed Refractory or Ineligible for Autologous Stem Cell Transplant (ASCT) Advanced Stage Classical Hodgkin Lymphoma (CheckMate 812: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 812)</scientifictitle>
    <utrn />
    <trialacronym>CheckMate 812</trialacronym>
    <secondaryid>2017-000847-41</secondaryid>
    <secondaryid>CA209-812</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hodgkin's Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Hodgkin's</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - Nivolumab
Other interventions - Brentuximab vedotin

Experimental: Module A - Nivolumab combined with Brentuximab

Experimental: Module B - Brentuximab alone


Other interventions: Nivolumab
Specified dose on specified days

Other interventions: Brentuximab vedotin
Specified dose on specified days

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression Free Survival (PFS) - To compare progression free survival of nivolumab + Brentuximab vedotin (BV) versus BV based on Blinded Independent Central Review (BICR) assessments</outcome>
      <timepoint>Up to four years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Complete Response Rate (CRR) - To compare the complete response rate of nivolumab + BV versus BV based on BICR assessments</outcome>
      <timepoint>Up to four years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Objective Response Rate (ORR) - To assess objective response rate and duration of response based on BICR</outcome>
      <timepoint>Up to four years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of response (DOR) - To assess duration of response based on BICR</outcome>
      <timepoint>Up to four years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of complete response (DOCR) - To assess duration of complete response based on BICR</outcome>
      <timepoint>Up to four years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival (OS) - To assess overall survival of participants treated with nivolumab + BV versus BV</outcome>
      <timepoint>Up to four years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression Free Survival (PFS) - To assess PFS based on investigator assessments</outcome>
      <timepoint>Up to four years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1

          -  Participants must have a pathologic diagnosis of classical Hodgkin lymphoma (cHL) who
             are relapsed or refractory with one of the following:

        I. Autologous stem cell transplant (ASCT) ineligible patients

        ii. Patients after failure of ASCT

          -  Must have at least one lesion that is &gt; 15 mm (1.5 cm) in the longest diameter and
             avid by Fluoro Deoxy Glucose (FDG) Positron Emission Tomography (PET) scan</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Known central nervous system lymphoma

          -  Participants with nodular lymphocyte-predominant Hodgkin lymphoma (HL)

          -  Participants with known history of pancreatitis or progressive multifocal
             leukoencephalopathy (PML)

        Other protocol defined inclusion/exclusion criteria could apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>16/05/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>340</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>27/07/2023</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC</recruitmentstate>
    <hospital>Local Institution - Albury</hospital>
    <hospital>Local Institution - Randwick</hospital>
    <hospital>Local Institution - Brisbane</hospital>
    <hospital>Local Institution - Woolloongabba</hospital>
    <hospital>Local Institution - Heidelberg</hospital>
    <postcode>2640 - Albury</postcode>
    <postcode>2031 - Randwick</postcode>
    <postcode>4029 - Brisbane</postcode>
    <postcode>4102 - Woolloongabba</postcode>
    <postcode>3084 - Heidelberg</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Prague 2</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Debrecen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Reggio Emilia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Ankara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Samsun</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bristol-Myers Squibb</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Seattle Genetics, Inc.</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine whether an investigational immuno-therapy
      combination, nivolumab with Brentuximab vedotin compared to Brentuximab vedotin alone is safe
      and effective in the treatment of relapsed and refractory Classical Hodgkin Lymphoma. The
      participants of this trial will comprise of patients who have relapsed or did not respond to
      treatment and are not eligible for stem cell transplant</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03138499</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bristol-Myers Squibb</name>
      <address>Bristol-Myers Squibb</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</name>
      <address />
      <phone>please email:</phone>
      <fax />
      <email>Clinical.Trials@bms.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>